Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly M. Seward, Todd M. Bauer, Raymond P. Perez, Ursula A. Matulonis, Kelli L. Running, Xiaoyan Zhang, Jose F. Ponte, Rodrigo Ruiz-Soto, Michael J. Birrer

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science